Get the Stockscreener App
6.49
5.26%
-0.36
After Hours:
6.53
0.04
+0.62%
Precigen Inc stock is traded at $6.49, with a volume of 5.53M.
It is down -5.26% in the last 24 hours and up +25.53% over the past month.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
See More
Previous Close:
$6.85
Open:
$6.97
24h Volume:
5.53M
Relative Volume:
1.09
Market Cap:
$2.32B
Revenue:
$9.68M
Net Income/Loss:
$-250.64M
P/E Ratio:
-4.6364
EPS:
-1.3998
Net Cash Flow:
$-89.83M
1W Performance:
-6.08%
1M Performance:
+25.53%
6M Performance:
+31.64%
1Y Performance:
+239.79%
1-Day Range:
$6.455
$6.97
1-Week Range:
$6.455
$7.32
52-Week Range:
$1.8044
$7.32
Precigen Inc Stock (PGEN) Company Profile
Name
Precigen Inc
Sector
Industry
Phone
301-556-9900
Address
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD
Compare PGEN vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PGEN
Precigen Inc
|
6.49 | 2.45B | 9.68M | -250.64M | -89.83M | -1.3998 |
VRTX
Vertex Pharmaceuticals Inc
|
516.44 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.97 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
856.94 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
202.00 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
356.01 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Precigen Inc Stock (PGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-22-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-23-23 | Initiated | JP Morgan | Neutral |
| Nov-18-22 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-21 | Initiated | Stifel | Buy |
| Feb-22-21 | Initiated | Wells Fargo | Overweight |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| May-08-20 | Initiated | H.C. Wainwright | Buy |
View All
Precigen Inc Stock (PGEN) Latest News
Precigen, Inc. (PGEN) Latest Stock News & Headlines - Yahoo! Finance Canada
Can Precigen (PGEN) Justify Its Valuation On Earnings And PAPZIMEOS Launch? - Yahoo Finance
US High Growth Tech Stocks To Watch: 3 Top Picks - simplywall.st
Precigen (PGEN) Q2 2026 Earnings Call Transcript - AOL.com
Precigen (PGEN) Is Up 16.3% After Papsimios-Fueled Return To Profitability And Broad Payer Coverage - webull.com
Precigen (PGEN) Insider Rutul Shah Sells 32,739 Shares - GuruFocus
Precigen jumps 266% on FDA approval but faces h... - Pluang
Wall Street Zen Upgrades Precigen (NASDAQ:PGEN) to "Strong-Buy" - MarketBeat
Precigen: Has To Grow Into Its Valuation - Seeking Alpha
Precigen (NASDAQ:PGEN) COO Sells $224,589.54 in Stock - MarketBeat
COO sale: Precigen (PGEN) insider trades 32,739 shares via plan - Stock Titan
Merck affiliates disclose 4.9% Precigen (NASDAQ: PGEN) ownership - Stock Titan
HC Wainwright Has Positive Outlook for Precigen Q3 Earnings - MarketBeat
Precigen (NASDAQ:PGEN) Stock Rating Upgraded by Zacks Research - MarketBeat
Precigen, Inc. (PGEN) Stock Analysis: Strong Growth Potential With An 80% Upside - DirectorsTalk Interviews
Precigen: 'Strong Buy' Papzimeos Cash-Flow Breakeven In '26, PRGN-2009 Advancement (PGEN) - Seeking Alpha
PRECIGEN, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $18 FROM $14 - webull.com
Precigen (NASDAQ: PGEN) Form 144 covers 32,739 common shares for sale - Stock Titan
HC Wainwright Predicts Precigen's Q4 Earnings (NASDAQ:PGEN) - MarketBeat
Results: Precigen, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - 富途牛牛
Precigen (NASDAQ:PGEN) Reaches New 12-Month HighShould You Buy? - MarketBeat
Arrowstreet Capital Limited Partnership Acquires Shares of 395,695 Precigen, Inc. $PGEN - MarketBeat
Precigen upgraded to Strong Buy on rising PAPZI... - Pluang
Precigen, Inc. (PGEN) Interactive Stock Chart - Yahoo! Finance Canada
Germantown biopharma Precigen turns first quarterly profit after key drug scores FDA approval - The Business Journals
Precigen (NASDAQ:PGEN) Shares Gap Up on Better-Than-Expected Earnings - MarketBeat
Precigen, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Precigen Inc (PGEN) (Q2 2026) Earnings Call Highlights: Revenue Surges 145% and Net Profit Achieved - GuruFocus
Is Precigen Inc (PGEN) Overvalued After Q2 Earnings Beat? GF Sco - GuruFocus
Earnings call transcript: Precigen tops Q2 2026 forecasts as PAPZIMEOS sales surge - Investing.com
Precigen (NASDAQ:PGEN) Announces Earnings Results - MarketBeat
Precigen, Inc. (PGEN) Q2 Earnings and Revenues Surpass Estimates - Yahoo Finance
Precigen, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Precigen (PGEN) Stock Rises on Q2 2026 Earnings - Quiver Quantitative
Q2 2026 Precigen Inc Earnings Call Transcript - GuruFocus
Earnings Flash (PGEN) Precigen, Inc. Reports Q2 Revenue $55.0M, vs. FactSet Est of $28.0M - marketscreener.com
PGEN: Profitability reached as PAPZIMEOS drives record revenue and broad US adoption - TradingView
PRECIGEN, INC. 2026: Revenue $54.98M, EPS $0.05— 10-Q Summary - TradingView
Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth - Yahoo Finance
Precigen earnings set to test gene therapy growth trajectory By Investing.com - Investing.com Nigeria
Precigen earnings set to test gene therapy growth trajectory - Investing.com
Analysts Offer Insights on Healthcare Companies: Precigen (PGEN) and Precision BioSciences (DTIL) - The Globe and Mail
Precigen COO Rutul Shah sells $219,518 in company stock - Investing.com
Precigen COO Rutul Shah sells $219,518 in company stock By Investing.com - Investing.com South Africa
Rutul Shah Sells 33,772 Shares of Precigen (NASDAQ:PGEN) Stock - MarketBeat
$Precigen (PGEN.US)$ 🏃🏃 Goodbye, brothers - Moomoo
Precigen (NASDAQ:PGEN) Earns Buy Rating from HC Wainwright - MarketBeat
Precigen, Inc. Revenue Breakdown – NASDAQ:PGEN - TradingView
Precigen, Inc. (PGEN) Investor Outlook: Exploring A Promising 110% Upside In Biotech - DirectorsTalk Interviews
Earnings Preview: Precigen to Report Financial Results Post-market on August 04 - Moomoo
Precigen (PGEN) Projected to Release Earnings on Tuesday - MarketBeat
Precigen Inc Stock (PGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.03%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):